At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry....
TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, has been awarded a £995,000 grant from Innovate UK.
Kadans Science Partner is set to welcome AviadoBio to its recently completed wet lab innovation and workspace centre at 20 Water Street in Canary Wharf.
Cell and Gene Therapy Catapult, Rentschler Biopharma, and Refeyn have announced a new partnership to develop and apply ‘innovative’ process analytical technologies (PAT) to improve the process and efficiency of AAV manufacture.
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.
Evox Therapeutics, an exosome therapeutics company, has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, US.
A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora,...
Dr. Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background,...
Syncona has launched Beacon Therapeutics, a new ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, with £96 million Series A financing.
Waters Corporation has officially completed its acquisition of Wyatt Technology, a leading provider of light scattering and field-flow fractionation instruments, software, accessories, and services.
Hansa Biopharma and Genethon have entered a research and development collaboration to test imlifidase as a gene therapy treatment in patients with pre-existing neutralizing antibodies.
BioMarin Pharmaceutical has opened the expansion of its manufacturing plant at Shanbally, Co. Cork: with the site now able to provide end-to-end manufacturing for a number of the company’s commercial products.
bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).
Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.
In an effort to improve its cash runway, the UK biotech company Freeline Therapeutics has paused the development of a gene therapy candidate for the rare metabolic condition Fabry disease. Instead, the company will refocus its efforts on a gene therapy...
Remedium Bio, a US biotech, and Exothera, a Belgian CDMO, have established a collaborative agreement in relation to the US firm’s disease modifying gene therapy for osteoarthritis, AAV2-FGF18.
Novartis has presented new data which ‘underscore the transformational and sustained benefit’ of spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec): with treated children maintaining motor milestones after 7.5 years.
Intergalactic Therapeutics, a startup focused on non-viral gene therapy, reports positive preclinical results for its lead program, IG-002, addressing all forms of ABCA4-related retinopathies.
Evonik has opened a new GMP facility to manufacture lipids for advanced pharmaceutical drug delivery applications, which is situated at the company’s site in Hanau, Germany.
Spark Therapeutics, a Roche company, has officially started work on its US$575m gene therapy innovation center in West Philadelphia. The center is expected to be completed by 2026.
Three months after receiving the US green light, CSL’s candidate Hemgenix has become the first gene therapy to gain EU approval for the treatment of hemophilia B.
In 2022, the European Medicines Agency (EMA) recommended 89 medicines for marketing authorization: including six advanced therapy medicinal products and eight biosimilars.
The Cell and Gene Therapy Catapult (CGT Catapult) has confirmed its involvement in the development of a new £900m ($1,097m) life science campus in Stevenage, UK: which is set to become one of the largest in Europe.
Pfizer currently has an unprecedented number of anticipated launches, says its CEO: with the company expecting to have up to 19 new products or indications in the market in the next 18 months.
Vector BioMed, a CDMO specializing in the manufacture of lentiviral vectors, launched this week; its first financing round was led by Viking Global Investors and Casdin Capital.
Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization...
The European Medicines Agency (EMA) is planning to alert healthcare professions about liver failure cases linked to Zolgensma, a gene therapy against spinal muscular atrophy (SMA), which is developed by Novartis.
Last week saw Opus Genetics announce it had acquired the rights to two preclinical-stage adeno-associated virus (AAV)-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio.
Replay, the genome writing company formed in July, has launched its third product company, Kaleibe, which will use HSV gene therapy to target genetic brain disorders.
France’s Polyplus has made two acquisitions of late, one to expand its plasmid DNA engineering technology and services portfolio, and another to enhance its GMP fill and finish capacities.
Annogen has begun a research project with Pfizer to functionally test tens of thousands of disease-related non-coding sequence variants for their effect on gene regulation.
Emmes has announced the creation of a dedicated center for cell and gene therapy research: which will focus on supporting clinical trials for the Clinical Research Organization’s (CRO) clients.
Gene therapy company Kriya Therapeutics is acquiring Redpin Therapeutics, a privately held biotech developing regulatable gene therapies for intractable diseases of the nervous system.
Chameleon Biosciences, a Berkeley-based biotech aiming to enable safer and more effective gene therapies, has won the Immunomodulatory Solution of the Year in the Biotech Breakthrough Awards, run by the Tech Breakthrough organization.
Sensorion, a biotech specializing in therapies for hearing loss disorders, has been granted Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its lead gene therapy candidate, OTOF-GT.
ReiThera has received operational authorization from the Italian Medicines Agency (AIFA) to open a new production area at its facility near Rome for the large-scale production of viral vectors for vaccines and gene therapy.
London investment fund Syncona will acquire retinal gene therapy company Applied Genetic Technologies Corporation (AGTC): with AGTC noting it had been facing ‘significant challenges’ in funding operations beyond 2022.
